Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer

Immune-checkpoint inhibitors (ICI) are promising modalities for treating triple negative breast cancer (TNBC). However, hyperglycolysis, a hallmark of TNBC cells, may drive tumor-intrinsic PD-L1 glycosylation and boost regulatory T cell function to impair ICI efficacy. Herein, we report a tumor micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xijiao, Cheng, Zhuo, He, Jinming, Yao, Xuemei, Liu, Yingqi, Cai, Kaiyong, Li, Menghuan, Hu, Yan, Luo, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622423/
https://www.ncbi.nlm.nih.gov/pubmed/37919262
http://dx.doi.org/10.1038/s41467-023-42883-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622423/
https://www.ncbi.nlm.nih.gov/pubmed/37919262
http://dx.doi.org/10.1038/s41467-023-42883-2

Ejemplares similares